Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.
In PNAS this week: analysis of Finland-United States Investigation of Non-Insulin-Dependent Diabetes Mellitus Genetics study samples, chromosome loss and gain in prostate cancer, and more.
Starting with a head and neck cancer patient who showed an impressive response to pembrolizumab, researchers profiled gene fusion neoantigens in several tumor types.
In the hunt for an antigen in solid tumors that CAR T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
Researchers reported finding oncohistone mutations within nearly 4 percent of tumors and said they could alter the structure and function of chromatin.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
